A pilot study for screening blood donors in Taiwan by nucleic acid amplification technology: detecting occult hepatitis B virus infections and closing the serologic window period for hepatitis C virus

Li, Lei; Chen, Pei‐Jer; Chen, Ming-Hung; Chak, Kin‐Fu; Lin, Kuo‐Sin; Tsai, Salina

doi:10.1111/j.1537-2995.2008.01672.x

Cited by 55 publications

(74 citation statements)

References 26 publications

(33 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In these cases, the viral load was low (Ͻ10 4 viral copies/ml) (9). In Taiwan, a study that used HBV NAT yielded 12 cases among 10,727 seronegative donations (0.11%) (18). The rate reported in this paper is 34 of 19,360 HBsAg-negative donations, or 0.18%.…”

Section: Discussionmentioning

confidence: 90%

Molecular Characteristics of Occult Hepatitis B Virus from Blood Donors in Southeast China

Yuan

Chen

et al. 2010

J Clin Microbiol

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 90%

Molecular Characteristics of Occult Hepatitis B Virus from Blood Donors in Southeast China

Yuan

Chen

et al. 2010

J Clin Microbiol

View full text Add to dashboard Cite

“…It is not common in general population even in HBV endemic areas. A recent study from Taiwan suggested that the prevalence of occult HBV infection was about 0.11% among healthy blood donors with a clean, automatic, and most sensitive nucleic acid amplification assay [46]. In contrast, occult HBV infection has been more frequently identified in patients with chronic HCV infection.…”

Section: Prevalence and Clinical Significance Of Occult Hbv Infectionmentioning

confidence: 99%

Dual chronic hepatitis B virus and hepatitis C virus infection

Liu

Chen

2009

Hepatol Int

Self Cite

View full text Add to dashboard Cite

Dual hepatitis B virus (HBV) and hepatitis C virus (HCV) infection are common in HBV or HCV endemic areas. However, several clinical and pathogenetic issues remain unresolved. First, clinical and in vitro studies suggest the interactions between two viruses. The dynamics of the interaction in untreated setting versus treated setting and its influence on the long-term outcomes await further studies. A key issue regarding viral interactions is whether modulation of infection occurs in the same dually infected individual hepatocyte of the liver. Clarifying this issue may help to understand the reciprocal interference between HCV and HBV and provide clues for future immunopathogenetic studies. Second, the prevalence and clinical significance of coexisting occult HBV infection in patients with chronic HCV infection need further investigations. Third, combination therapy of peginterferon alfa2a and ribavirin appears to be just as effective and safe for the treatment of hepatitis B surface antigen (HBsAg)-positive patients chronically infected with active chronic hepatitis C as it is in patients with HCV monoinfection. Nevertheless, one-third of dually infected patients with nondetectable serum HBV DNA-level pretreatment developed HBV reactivation posttreatment. How to prevent and treat this reactivation should be clarified. Furthermore, about 10% of the dually infected patients lost HBsAg. Underlying mechanisms await further investigations. Finally, the optimal treatment strategies for dually infected patients with hepatitis B e antigen-positive chronic hepatitis B should be identified in future clinical trials.

show abstract

“…This finding confirmed the significance of OBI risk in hyperendemic areas and a large proportion of anti-HBc deferrals among noninfectious donors, reinforcing the advantages of HBV NAT in such areas. HBV NAT yield was estimated at 0.11% or 1 : 909 and was evaluated as cost-effective in endemic areas [52]. A lookback study based on repository samples found 1.1% of them with OBI but none of the blood recipients with HBsAg seroconversion or clinical symptoms of posttransfusion HBV [53].…”

Section: Developed Countriesmentioning

confidence: 99%

Residual Risk of Hepatitis-B-Infected Blood Donations: Estimation Methods and Perspectives

Kupek

2013

ISRN Infectious Diseases

View full text Add to dashboard Cite

Despite a considerable reduction of the risk of HBV-infected blood donation entering blood supply (residual risk) due to improved screening by HBV NAT in the developed countries, the bulk of the people with HBV living in the developing countries still needs to be screened by serologic tests such as HBsAg and anti-HBc. Many of these countries lack resources for implementing NAT and are likely to remain so in the next decade or longer, thus depending on the HBV residual risk monitoring based on serologic testing and corresponding estimation methods. This paper reviews main HBV residual risk findings worldwide and the methods based on serology used for their calculation with repeat donors, as well as their extension to the first-time donors. Two artificial datasets with high (4.36%) and low (0.48%) HBV prevalence were generated to test the performance of five methods: the original incidence/window-period model based solely on HBsAg, its modification by Soldan in 2003, the Müller-Breitkreutz model, the HBsAg yield model, and its extension to include anti-HBc seroconversions within a year. The last model was closest to the true values of residual risk and had smallest variation of the estimates in both high and low prevalence data. It may be used for residual risk evaluation in relatively small samples, such as regional blood banks data.

show abstract

A pilot study for screening blood donors in Taiwan by nucleic acid amplification technology: detecting occult hepatitis B virus infections and closing the serologic window period for hepatitis C virus

Cited by 55 publications

References 26 publications

Molecular Characteristics of Occult Hepatitis B Virus from Blood Donors in Southeast China

Molecular Characteristics of Occult Hepatitis B Virus from Blood Donors in Southeast China

Dual chronic hepatitis B virus and hepatitis C virus infection

Residual Risk of Hepatitis-B-Infected Blood Donations: Estimation Methods and Perspectives

Contact Info

Product

Resources

About